Inhibrx Stock Financials

INBX -  USA Stock  

USD 25.87  2.19  7.80%

Understanding current and past Inhibrx Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Inhibrx's financial statements are interrelated, with each one affecting the others. For example, an increase in Inhibrx's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Inhibrx's financials over time to get the whole picture.
Inhibrx Tangible Asset Value is fairly stable at the moment as compared to the past year. Inhibrx reported Tangible Asset Value of 165.3 Million in 2021. Working Capital is likely to rise to about 125 M in 2022, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (61.1 M) in 2022.
Use fundamental data analysis to validate all available fundamentals of Inhibrx to find out if markets are presently mispricing the company. We have analyzed twenty-six available reported financial drivers for Inhibrx, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Inhibrx financials, including its cash and equivalents, and the relationship between the price to sales and book value per share . Given that Inhibrx has a number of shares shorted of 685.9 K, we strongly advise you to confirm Inhibrx regular market performance to make sure the company can sustain itself down the road. Use Inhibrx to protect your portfolios against small market fluctuations. The stock experiences a very speculative upward sentiment. Check odds of Inhibrx to be traded at $24.58 in 90 days.

Inhibrx Fundamentals 

 
Refresh
With this module, you can analyze Inhibrx financials for your investing period. You should be able to track the changes in Inhibrx individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Inhibrx is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Inhibrx includes many different criteria found on its balance sheet. For example, investors should never minimize Inhibrx's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Inhibrx's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Inhibrx.

Inhibrx Cash

Chance Of Financial Distress
Less than 33
Inhibrx has less than 33 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Inhibrx stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Inhibrx's official financial statements usually reflect Inhibrx's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Inhibrx. For example, before you start analyzing numbers published by Inhibrx accountants, it's critical to develop an understanding of what Inhibrx's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Inhibrx's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inhibrx's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Inhibrx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibrx. Please utilize our Beneish M Score to check the likelihood of Inhibrx's management to manipulate its earnings.

Inhibrx Company Summary

Inhibrx competes with Amicus Therapeutics, and Brickell Biotech. Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP45720L107
LocationCalifornia; U.S.A
Business Address11025 North Torrey
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websiteinhibrx.com
Phone858 795 4220
CurrencyUSD - US Dollar
You should never invest in Inhibrx without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Inhibrx Stock, because this is throwing your money away. Analyzing the key information contained in Inhibrx's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Inhibrx Key Financial Ratios

Generally speaking, Inhibrx's financial ratios allow both analysts and investors to convert raw data from Inhibrx's financial statements into concise, actionable information that can be used to evaluate the performance of Inhibrx over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Inhibrx reports annually and quarterly.

Inhibrx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Inhibrx's current stock value. Our valuation model uses many indicators to compare Inhibrx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inhibrx competition to find correlations between indicators driving Inhibrx's intrinsic value. More Info.
Inhibrx is rated second overall in shares owned by institutions category among related companies. It is rated second overall in cash flow from operations category among related companies . Net Cash Flow from Operations is likely to drop to about (46.6 M) in 2022. Free Cash Flow is likely to drop to about (47.9 M) in 2022. Comparative valuation analysis is a catch-all model that can be used if you cannot value Inhibrx by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inhibrx's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inhibrx's earnings, one of the primary drivers of an investment's value.

Inhibrx Systematic Risk

Inhibrx's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Inhibrx volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Inhibrx correlated with the market. If Beta is less than 0 Inhibrx generally moves in the opposite direction as compared to the market. If Inhibrx Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Inhibrx is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Inhibrx is generally in the same direction as the market. If Beta > 1 Inhibrx moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Inhibrx Financials

What exactly are Inhibrx Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Inhibrx's income statement, its balance sheet, and the statement of cash flows. Potential Inhibrx investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Inhibrx investors may use each financial statement separately, they are all related. The changes in Inhibrx's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inhibrx's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2019 2020 2021 2022 (projected)
Current Assets15.56 M132.17 M152 M164 M
Total Assets26.49 M143.74 M165.3 M178.35 M
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Inhibrx is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Inhibrx grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Inhibrx January 24, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Inhibrx help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Inhibrx. We use our internally-developed statistical techniques to arrive at the intrinsic value of Inhibrx based on widely used predictive technical indicators. In general, we focus on analyzing Inhibrx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Inhibrx's daily price indicators and compare them against related drivers.
Information Ratio(0.09)
Maximum Drawdown25.91
Value At Risk(7.93)
Potential Upside5.48
Please see Risk vs Return Analysis. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Is Inhibrx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.